A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Study Summary

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.

Conditions

Ovarian Cancer Clear Cell Carcinoma Endometrial Cancer Cervical Carcinoma Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions / Drugs

vudalimab

View on ClinicalTrials.gov ↗

Sponsor

XNCR

Xencor Inc

Bispecific Antibodies

D38/100

Study Details

Enrollment170 participants

Primary Completion—

Lead SponsorXencor, Inc.

Data Retrieved2026-04-11 04:31:58.925889+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.